

* Deal deepens oncology push under CEO Luke Miels


* Deal deepens oncology push under CEO Luke Miels


June 9 (Reuters) - Britain's blue-chip FTSE 100 hit its lowest since mid-May on Tuesday, bogged down by losses in heavyweight lenders HSBC and Stan...


* Deal values cancer drug developer Nuvalent at $124 per share


SAN FRANCISCO, Jan 26 (Reuters) - Artificial intelligence has yet to deliver on the most challenging aspect of drug development -- finding new molecu...